Analysts Are Bullish on Top Healthcare Stocks: Endo International (ENDP), ANI Pharmaceuticals Inc (ANIP)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Endo International (NASDAQ:ENDP) and ANI Pharmaceuticals Inc (NASDAQ:ANIP) with bullish sentiments.

Endo International (ENDP)

In a report released yesterday, David Buck from B.Riley FBR maintained a Buy rating on Endo International, with a price target of $18.50. The company’s shares opened today at $16.06, close to its 52-week high of $17.34.

Buck said:

“Endo International (ENDP) shares remain Buy-rated and we reiterate our $18.50 per share target using 8x 2019E adjusted EBITDA. Our bullish thesis has included bottoming of generic pricing plus growth for the Branded Sterile Injectables business, which is higher- margin including products with patents/IP protection such as branded Vasostrict (vasopressin). Vasostrict, Endo’s largest drug, at ~$439M for 2018E sales, accounts for ~15% of total Endo sales and a higher profit percentage. Recently, an outsourcing pharmacy, Athenex (ATNX) announced that it has launched a bulk vasopressin and intends to gain share without disrupting the market too much. Today, 8/15, Endo lifted its temporary stay of FDA litigation in response to the competitive threat from Athenex.”

According to TipRanks.com, Buck is a 4-star analyst with an average return of 11.9% and a 70.4% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Endo International with a $16.68 average price target, which is a 3.9% upside from current levels. In a report issued on August 13, RBC Capital also upgraded the stock to Buy with a $26 price target.

.

See today’s analyst top recommended stocks >>

ANI Pharmaceuticals Inc (ANIP)

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on ANI Pharmaceuticals Inc today and set a price target of $75. The company’s shares opened today at $56.28.

Steadman observed:

“We remain BUY rated on ANIP shares, but are reducing our DCF-driven PT to $75.”

According to TipRanks.com, Steadman is a 3-star analyst with an average return of 2.5% and a 35.5% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Perrigo Company plc, and Endo International.

ANI Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $72.67, representing a 29.1% upside. In a report issued on August 7, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $74 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts